Pharmaceuticals Acquisitions in 2026

Ampersand Capital Partners acquired Purna Pharmaceuticals, a Belgian contract development and manufacturing provider of liquid and semi-solid pharmaceutical dosage forms. The investment positions Purna to collaborate with Ampersand portfolio company MedPharm to create a trans‑Atlantic topical and transdermal development and manufacturing offering; Creafund, Purna's prior investor, supported the company for more than a decade and was referenced in the transaction announcement.

Alkermes plc completed its all-cash acquisition of Avadel Pharmaceuticals plc under an Irish High Court‑sanctioned scheme of arrangement, adding Avadel's FDA‑approved product LUMRYZ to Alkermes' commercial portfolio. The deal accelerates Alkermes' entry into the sleep medicine market, is expected to be accretive in 2026, and includes Avadel's clinical candidate valiloxybate.

BioSelective Capital Investments, together with Shayan Enterprises, LLC, acquired BioDuro’s drug product development and manufacturing operations in Irvine, California and formed Forma Life Sciences, Inc. The transaction transfers two U.S.-based oral solid dosage development and manufacturing facilities (≈65,000 sq ft and ≈40,000 sq ft) to the new Delaware-held company; BioDuro (an Advent portfolio company) sold the assets.

Cycle Group Holdings Limited (Cycle Pharmaceuticals) has completed the acquisition of NASDAQ-listed Applied Therapeutics, a clinical-stage biopharmaceutical company focused on novel CNS-penetrant therapies for rare metabolic diseases. The transaction was funded from Cycle's cash on hand and brings Applied's lead candidate govorestat and rare-disease pipeline into Cycle's rare metabolic disease platform.

Mirum Pharmaceuticals has completed the acquisition of Bluejay Therapeutics, adding brelovitug — a late‑stage monoclonal antibody for chronic hepatitis delta virus (HDV) — to its rare liver disease pipeline. The deal gives Mirum worldwide rights to the AZURE Phase 3 program and includes a combination of cash and Mirum common stock with potential sales‑based milestone payments; Mirum also raised approximately $268.5M in concurrent financing to support development and commercialization.

Agno Pharma has acquired Actylis Eugene, the legacy Cascade Chemistry manufacturing asset in Eugene, Oregon, expanding Agno's U.S. cGMP API development and manufacturing footprint. The site includes a 16,000 sq. ft. R&D lab and a newly constructed 30,000 sq. ft. GMP manufacturing facility, enhancing Agno's capabilities to support biotech and pharmaceutical clients from early-phase through commercial API production.

Fagron has completed the acquisition of University Compounding Pharmacy (UCP), a San Diego–based 503A compounding pharmacy focused on hormone and urology therapies. The transaction values UCP at approximately $41.5 million; UCP generates roughly $25 million of annual revenue. Fagron said the purchase supports its strategy to build a nationwide U.S. compounding platform (complementary to Anazao) and strengthens its presence in California.

Fagron NV has completed the acquisition of University Compounding Pharmacy (UCP), a San Diego–based 503A compounding pharmacy focused on health and wellness, hormones and urology. The transaction has an enterprise value of approximately $41.5 million; UCP had annual revenues of around $25 million and will be integrated to strengthen Fagron's U.S. compounding platform alongside Anazao, with synergies expected over 18–24 months.

PAI Pharma, an Olympus Partners portfolio company, has acquired Nivagen Pharmaceuticals to add a newly built aseptic sterile-injectable manufacturing facility in Sacramento, California and a pipeline of more than 20 ready-to-use (RTU) injectable products. The add-on expands PAI's sterile injectable capabilities alongside its oral liquid franchise to better serve hospitals and health systems and strengthen U.S. pharmaceutical supply-chain resilience; financial terms were not disclosed.

Fagron has completed the acquisition of Purifarma, a large-scale pharmaceutical essentials business in Brazil, for an enterprise value of approximately R$250 million. The deal strengthens Fagron's scale and procurement position in Latin America and supports the Group's buy-and-build strategy to expand its pharmaceutical compounding and essentials platform.

Fagron has completed the acquisition of Purifarma in Brazil following CADE approval, strengthening Fagron's scale in Essentials and advancing its buy-and-build strategy. Purifarma is a large-scale distributor/importer of pharmaceutical, food and cosmetic inputs; the transaction carries an enterprise value of approximately R$250 million and is expected to deliver product-mix improvements, access to industrial customers and purchasing synergies across Latin America.

SHINE Technologies has completed the acquisition of Lantheus' SPECT business, including the North Billerica, Massachusetts SPECT manufacturing facility and a portfolio of diagnostic radiopharmaceuticals (TechneLite, Cardiolite, NEUROLITE, Xenon Xe-133). SHINE named Michael Rossi CEO of SHINE SPECT USA, LLC and said the acquisition expands its nuclear medicine manufacturing capabilities and integrates with its Chrysalis Mo-99 production to strengthen isotope supply chain security.